However, cell pre-treatment with type I or III IFN increases antiviral activity and restricts SARS-CoV-2 replication, indicating that the virus is susceptible to type I and III IFNs if the antiviral state is induced before the infection. The gene discussed is IFNA1; the disease is infection.